# A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

> **NCT00185094** · PHASE4 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 60 (—)

## Conditions studied

- Hypertension
- Insulin Resistance
- Metabolic Syndrome

## Interventions

- **DRUG:** Olmesartan medoxomil
- **DRUG:** Losartan potassium
- **DRUG:** Atenolol

## Key facts

- **NCT ID:** NCT00185094
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185094, "A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00185094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*